Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biofrontera Inc BFRI

Healthcare
Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial... see more

Recent & Breaking News (NDAQ:BFRI)

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

GlobeNewswire 8 days ago

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024

Accesswire November 1, 2024

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

GlobeNewswire October 31, 2024

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

GlobeNewswire October 14, 2024

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

GlobeNewswire October 7, 2024

Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference

Accesswire September 25, 2024

Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire August 14, 2024

Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024

Accesswire August 9, 2024

Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

GlobeNewswire June 24, 2024

Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update

Accesswire May 15, 2024

Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024

Accesswire May 6, 2024

Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants

Accesswire May 3, 2024

Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals

Accesswire March 26, 2024

CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update

Accesswire March 15, 2024

Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update

Accesswire March 15, 2024

Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024

Accesswire March 8, 2024

Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules

Accesswire February 23, 2024

Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG

Accesswire February 20, 2024

Biofrontera Inc. Announces Private Placement of Up To $16.0 Million Priced at Market per Nasdaq Rules

Accesswire February 20, 2024

Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use

Accesswire February 5, 2024